Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: A dosing strategy for aspergillus infections

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 4, 2009, Pages 840-844

  Ikawa, Kazuro ^a   Nomura, Kenichi ^b   Morikawa, Norifumi ^a   Ikeda, Kayo ^a   Taniwaki, Masafumi ^b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Echinocandins; Monte Carlo simulation; Population pharmacokinetics

Indexed keywords

MICAFUNGIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA ALBICANS; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; HUMAN; MALE; MONTE CARLO METHOD;

ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; ECHINOCANDINS; FEMALE; HUMANS; LIPOPEPTIDES; MALE; MIDDLE AGED; MODELS, STATISTICAL; PLASMA;

EID: 70349456240     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp298     Document Type: Article

References (15)

1. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
2. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
3. Gumbo T, Drusano GL, Liu W et al. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother 2007; 51: 968-74.
4. Andes DR, Diekema DJ, Pfaller MA et al. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008; 52: 3497-503.
5. Antachopoulos C, Meletiadis J, Sein T et al. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob Agents Chemother 2008; 52: 321-8.
6. Shimoeda S, Ohta S, Kobayashi H et al. Effective blood concentration of micafungin for pulmonary aspergillosis. Biol Pharm Bull 2006; 29: 1886-91.
7. Nicasio AM, Tessier PR, Nicolau DP et al. Bronchopulmonary disposition of micafungin in healthy adult volunteers. Antimicrob Agents Chemother 2009; 53: 1218-20.
8. Mouton JW, Dudley MN, Cars O et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: An update. J Antimicrob Chemother 2005; 55: 601-7.
9. Pfaller MA, Boyken L, Hollis RJ et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: Six years of global surveillance. J Clin Microbiol 2008; 46: 150-6.
10. Tabata K, Katashima M, Kawamura A et al. Pharmacokinetics-pharmacodynamics of micafungin in Japanese patients with deep-seated mycosis. Eur J Drug Metab Pharmacokinet 2006; 31: 123-8.
11. Tabata K, Katashima M, Kawamura A et al. Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infections. Drug Metab Pharmacokinet 2006; 21: 324-31.
12. Gumbo T, Hiemenz J, Ma L et al. Population pharmacokinetics of micafungin in adult patients. Diagn Microbiol Infect Dis 2008; 60: 329-31.
13. Dowell JA, Knebel W, Ludden T et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004; 44: 590-8.
14. Denning DW, Marr KA, Lau WM et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337-49.
15. Kontoyiannis DP, Ratanatharathorn V, Young JA et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis 2009; 11: 89-93.